Phase I Study of HC-7366 for Acute Myeloid Leukemia
This study is testing a new drug called HC-7366 for people with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) that has become AML. The main goal is to find a safe dose of HC-7366 and see what side effects it might cause. Researchers will also look at how well HC-7366 works to treat the cancer. You might be able to join if you are 18 or older, have AML or MDS/AML, and your cancer has come back or not responded to previous treatments. The study is currently unclear about its recruitment status and plans to enroll 18 participants.
- Study design
- This is a Phase I interventional study, which means it's one of the first times this drug is being tested in people. It aims to enroll 18 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and any side effects will be monitored throughout the study, which is expected to last about one year on average.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase I Study of HC-7366 for Acute Myeloid Leukemia
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Abhishek Maiti, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0